CD8A and neoplasm: We used the BR-Luc syngeneic model to investigate the relation between anti-tumor efficacy and the presence of immune infiltrates, including the impact on FRβ-expressing TAMs and CD3+, CD4+ and CD8+ T cells, accompanying treatment with the pyrrolo[2,3-d]pyrimidine antifolate inhibitor AGF94.